Organigram Global Inc.
NASDAQ:OGIDrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $95.40M
- Beta
- 1.84
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$0.19
Volume 0.62M
Average 0.67M
OGI Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Organigram Global Inc.NASDAQ: OGI
Cash & Equivalents · Q2 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 310.3% from a year ago
Cash & equivalents stood at CA$54.08M at the end of Q2 FY2026, up 310.3% from a year earlier and down 12.9% from the prior quarter.
Context
- Cash & equivalents amounted to 10.3% of total assets at the end of Q2 FY2026, up 7.9 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +310.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
CAD · from the balance sheet
- Latest · FY2025
- 28.2M CAD
- Year-over-year change
- -73.6%
- 4-year CAGR
- -15.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 28.2M | -73.6% |
| FY2024 | 2024-09-30 | 106.75M | +215.2% |
| FY2023 | 2023-09-30 | 33.86M | -50.6% |
| FY2022 | 2022-08-31 | 68.52M | +23.8% |
| FY2021 | 2021-08-31 | 55.37M | — |
Cash & Equivalents vs competitors
How OGI compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +310.3% is the highest of 9, against a peer median of +20.3%.
- Cash & equivalents amounts to 10.3% of total assets for OGI, versus a peer median of 28.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $118.64M USD | -34.2% | +5.5% | 41.1% | |
| Mar 2026 | CA$112.77M CAD | -38.8% | -27.9% | 18.7% | |
| Dec 2025 | €99.27M EUR | +2.8% | +4.6% | 39.9% | |
| Mar 2026 | CA$54.08M CAD | +310.3% | — | 10.3% | |
| Mar 2026 | $28.37M USD | +54.6% | +20.6% | 28.2% | |
| Mar 2026 | $27.22M USD | +29.2% | -9.0% | 29.7% | |
| Dec 2025 | $17.47M USD | — | — | 7.5% | |
| Mar 2026 | $16.99M USD | +11.5% | +23.3% | 28.6% | |
| Mar 2026 | $4.4M USD | +296.3% | -20.6% | 2.2% | |
| Mar 2026 | $2.11M USD | +39.8% | +168.3% | 2.1% | |
| Peer median (excluding OGI) | — | +20.3% | +5.1% | 28.2% | |
Competitors are the stored peer set for OGI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Aug 2021 | FY2022 Aug 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 55.37M | 68.52M | 33.86M | 106.75M | 28.2M |
| Short-term Investments | 128.48M | 30.4M | 0 | 821K | 826K |
| Net Receivables | 21M | 46.37M | 27.46M | 37.15M | 64.86M |
| Inventory | 48.82M | 68.28M | 80.95M | 82.52M | 123.95M |
| Other Current Assets | 5.51M | 2.21M | 13.7M | 25.86M | 55.39M |
| Total Current Assets | 260.62M | 221.62M | 155.98M | 262.22M | 284.9M |
| Property, Plant & Equipment (Net) | 235.94M | 259.82M | 99.05M | 96.23M | 122.98M |
| Goodwill | 14.32M | 41.98M | 0 | 0 | 52.52M |
| Intangible Assets | 2.73M | 14.26M | 10.62M | 8.09M | 48.51M |
| Long-term Investments | 6.11M | 7.07M | 13.72M | 40.73M | 49.55M |
| Tax Assets | 3.2M | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 31.11M | 32.36M | 19.09M | 591K | 3.75M |
| Total Non-current Assets | 293.4M | 355.48M | 142.48M | 145.64M | 277.31M |
| Total Assets | 554.02M | 577.11M | 298.46M | 407.86M | 562.21M |
| Account Payables | 18.95M | 40.86M | 14.73M | 47.1M | 89.25M |
| Short-term Debt | 80K | 80K | 76K | 60K | 25K |
| Tax Payables | 0 | 1.42M | 94K | 0 | 0 |
| Deferred Revenue | 0 | 2.44M | 0 | 0 | 0 |
| Other Current Liabilities | 6.25M | 12M | 2.35M | 5.14M | 35.91M |
| Total Current Liabilities | 26.27M | 55.29M | 22.43M | 53.32M | 126.16M |
| Long-term Debt | 230K | 155K | 3.63M | 25K | 0 |
| Deferred Tax Liabilities | 0 | 3.62M | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 43.07M | 7.79M | 771K | 45.18M | 79.17M |
| Total Non-current Liabilities | 47.95M | 13.76M | 4.4M | 48.55M | 86.92M |
| Total Liabilities | 74.21M | 69.05M | 26.83M | 101.87M | 213.08M |
| Common Stock | 730.8M | 769.73M | 776.91M | 852.89M | 919.91M |
| Retained Earnings | (275.64M) | (289.93M) | (538.53M) | (583.97M) | (608.73M) |
| Accumulated OCI | 24.65M | 28.26M | 33.25M | 37.07M | 37.95M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 479.81M | 508.06M | 271.62M | 305.99M | 349.13M |
| Total Debt | 5.95M | 3.36M | 3.71M | 4.46M | 8.75M |
| Net Debt | (49.42M) | (65.16M) | (30.16M) | (102.29M) | (19.45M) |
Organigram Global Inc.
NASDAQ:OGI
Intrinsic Alpha fair value
Locked
Current Price
$0.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.